Close Menu

Clostridium difficile

A Drug or What?

The FDA has yet to determine if fecal microbiome transplants should be treated like a drug or like a blood transfusion, the New York Times reports.

Signature Science will assess the validity of metagenomic and metatranscriptomic analyses to detect the transmission of viable pathogens in healthcare settings.

Researchers hope that understanding the etiology of inappropriate testing will help them design a better computerized support tool.

Researchers in the US and Europe are implementing pathogen sequencing surveillance programs to track infectious diseases within hospitals.

The firm saw strong growth in respiratory illness assays and lead testing, which was offset by a decline in C. difficile testing.

Palmetto GBA's decision that large syndromic MDx panels may not always be necessary prompted GenePOC's decision to further target smaller panels.

The test, which runs on the firm's Revogene molecular diagnostics instrument, has now been launched in Canada.

Meridian's diagnostics revenues grew 1 percent year over year to $36.4 million while its life science revenues jumped 8 percent to $15.4 million.

Why Do It?

Researchers examine what motivates people to become donors for fecal microbiome transplants, according to the New York Times.

"Repurposing starts with the human genome," a precision medicine expert said in explaining Vanderbilt's new approach to accelerating clinical trials.

Pages

The New York Times Magazine examines gender discrimination at the Salk Institute.

Science reports that MD Anderson Cancer Center has dismissed three researchers over foreign tie concerns.

A second death in gene therapy trial for type 1 spinal muscular atrophy is under investigation, according to Reuters.

In PLOS this week: antibiotic resistance patterns in Escherichia coli, a dozen genetic loci tied to varicose vein risk, and more.